Organon & Co. Financials
Quarterly XBRL submissions from SEC 10-K and 10-Q filings.
Income Statement (Last 8 Quarters)
(3)| Period | Revenue | YoY % | Net Income | YoY % | Operating Income | EPS |
|---|---|---|---|---|---|---|
| Q3 FY202510-Q · 2025-09-30 | $1.6B | — | $160.0M | — | — | $0.61 |
| Q2 FY202510-Q · 2025-06-30 | $50.0M | — | $145.0M | — | — | $0.56 |
| Q1 FY202510-Q · 2025-03-31 | $240.0M | — | $87.0M | — | — | $0.33 |
Balance Sheet
| Period | Total Assets | Total Liabilities | Cash & Equivalents | Shareholders Equity |
|---|---|---|---|---|
| Q3 FY202510-Q | $13.6B | $12.6B | $672.0M | $906.0M |
| Q2 FY202510-Q | $13.5B | $12.8B | $599.0M | -$572.0M |
| Q1 FY202510-Q | $13.2B | $12.6B | $547.0M | $542.0M |
Cash Flow Highlights
| Period | Operating Income | Net Income | Gross Profit | Shares Outstanding |
|---|---|---|---|---|
| Q3 FY202510-Q | — | $160.0M | $857.0M | 259,983,000 |
| Q2 FY202510-Q | — | $145.0M | $874.0M | 259,965,000 |
| Q1 FY202510-Q | — | $87.0M | $841.0M | 257,950,000 |
Filings
(4)Methodology
Every figure on this page is pulled directly from Organon & Co.'s own XBRL submissions to the U.S. Securities and Exchange Commission. XBRL is the standardized tagging format the SEC requires for line items in 10-K and 10-Q filings, which means revenue, net income, and balance-sheet entries are reported by the company itself — not estimated by us.
Cayman Journal reconciles preferred GAAP tags (for example, Revenues, RevenueFromContractWithCustomerExcludingAssessedTax) and normalizes them so quarter-over-quarter comparability is preserved. Our automated ingestion runs nightly; markets editors spot-check flagged anomalies before they appear on the public hub. Where a tag is missing for a given period, we surface an em dash rather than impute a value.
Source documents are linked under Filings above and point to the original EDGAR submission index. Errors should be reported to [email protected].